Johnson & Johnson Family of Companies
NEWS
Now insiders say J&J has decided it is no longer interested.
But for now, the world’s biggest healthcare company isn’t providing many details on how it may use the extra money from lower tax rates.
Most investors and analysts are expecting 2018 to be a big year for mergers and acquisitions.
The USPTO is paving the way for generic challengers to J&J’s prostate cancer drug Zytiga.
Chinese interest in the J&J unit comes as the market for diabetes care in China is expected to grow rapidly.
A federal judge has temporarily blocked the Trump administration’s efforts to wind down DACA.
A cybersecurity expert said the error may leave people vulnerable to hackers.
Will this new buy be enough for Celgene investors?
The latest collaborations bring the total number of strategic transactions executed by J&J Innovation to more than 350 since its establishment in 2012.
JOBS
IN THE PRESS